• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Preoperative Liver Function Guiding HCC Resection in Normal and Cirrhotic Liver.术前肝功能指导正常肝脏和肝硬化肝脏中的肝癌切除术
Visc Med. 2021 Mar;37(2):94-101. doi: 10.1159/000508172. Epub 2020 Jun 12.
2
Value of Preoperative Indocyanine Green Clearance Test for Predicting Post-Hepatectomy Liver Failure in Noncirrhotic Patients.术前吲哚菁绿清除试验预测非肝硬化患者肝切除术后肝衰竭的价值。
Med Sci Monit. 2017 Oct 18;23:4973-4980. doi: 10.12659/msm.907306.
3
The predictive value of future liver remnant function after liver resection for HCC in noncirrhotic and cirrhotic patients.肝切除术后非肝硬化和肝硬化患者剩余肝功能的预测价值。
HPB (Oxford). 2019 Jul;21(7):912-922. doi: 10.1016/j.hpb.2018.11.012. Epub 2019 Feb 4.
4
The LiMAx test: a new liver function test for predicting postoperative outcome in liver surgery.LiMAx 试验:一种新的肝功能试验,可预测肝外科术后结局。
HPB (Oxford). 2010 Mar;12(2):139-46. doi: 10.1111/j.1477-2574.2009.00151.x.
5
LiMAx Prior to Radioembolization for Hepatocellular Carcinoma as an Additional Tool for Patient Selection in Patients with Liver Cirrhosis.在肝细胞癌放射性栓塞治疗前使用LiMAx作为肝硬化患者患者选择的附加工具。
Cancers (Basel). 2022 Sep 21;14(19):4584. doi: 10.3390/cancers14194584.
6
Effectiveness comparison of indocyanine green retention test with the cirrhotic severity scoring in evaluating the pathological severity of liver cirrhosis in patients with hepatocellular carcinoma and Child-Pugh grade A liver function.吲哚菁绿滞留试验与肝硬化严重程度评分在评估肝功能 A 级的肝细胞癌合并肝硬化患者的病理严重程度中的有效性比较。
World J Surg Oncol. 2020 Apr 23;18(1):79. doi: 10.1186/s12957-020-01854-3.
7
Use of the liver maximum function capacity test (LiMAx) for the management of liver resection in cirrhosis - A case of hypopharyngeal cancer liver metastasis.肝脏最大功能容量测试(LiMAx)在肝硬化肝切除管理中的应用——1例下咽癌肝转移病例
Int J Surg Case Rep. 2017;39:140-144. doi: 10.1016/j.ijscr.2017.08.003. Epub 2017 Aug 10.
8
LiMAx Test Improves Diagnosis of Chemotherapy-Associated Liver Injury Before Resection of Colorectal Liver Metastases.LiMAx 试验可改善结直肠癌肝转移切除术前化疗相关肝损伤的诊断。
Ann Surg Oncol. 2017 Sep;24(9):2447-2455. doi: 10.1245/s10434-017-5887-2. Epub 2017 May 17.
9
Volume-Function Analysis (LiMAx Test) in Patients with HCC and Cirrhosis Undergoing TACE-A Feasibility Study.肝癌合并肝硬化患者行 TACE 治疗前后的容积-功能分析(LiMAx 试验):一项可行性研究。
Dig Dis Sci. 2021 Jul;66(7):2452-2460. doi: 10.1007/s10620-020-06535-5. Epub 2020 Aug 20.
10
An ordinal model to predict the risk of symptomatic liver failure in patients with cirrhosis undergoing hepatectomy.一种用于预测行肝切除术的肝硬化患者发生症状性肝衰竭风险的有序模型。
J Hepatol. 2019 Nov;71(5):920-929. doi: 10.1016/j.jhep.2019.06.003. Epub 2019 Jun 14.

引用本文的文献

1
Evaluation of hepatic functional reserve of hepatocellular carcinoma (≤ 5 cm) by liver shear wave velocity combined with multiple parameters.肝脏剪切波速度联合多参数评估肝细胞癌(≤5 cm)的肝功能储备
Front Oncol. 2024 Mar 14;14:1301052. doi: 10.3389/fonc.2024.1301052. eCollection 2024.
2
Preoperative predictors for non-resectability in perihilar cholangiocarcinoma.肝门周围胆管癌不可切除的术前预测因素。
World J Surg Oncol. 2024 Feb 7;22(1):48. doi: 10.1186/s12957-024-03329-1.
3
Postoperative Liver Failure: Definitions, Risk factors, Prediction Models and Prevention Strategies.术后肝功能衰竭:定义、危险因素、预测模型和预防策略。
J Gastrointest Surg. 2023 Nov;27(11):2640-2649. doi: 10.1007/s11605-023-05834-2. Epub 2023 Oct 2.
4
Evaluation of liver function using Gd-EOB-DTPA-enhanced MRI with T1 mapping.使用 Gd-EOB-DTPA 增强 MRI 与 T1 映射评估肝功能。
BMC Med Imaging. 2023 Jun 5;23(1):73. doi: 10.1186/s12880-023-01028-z.
5
Liver Function-How to Screen and to Diagnose: Insights from Personal Experiences, Controlled Clinical Studies and Future Perspectives.肝功能——如何筛查与诊断:来自个人经验、对照临床研究及未来展望的见解
J Pers Med. 2022 Oct 5;12(10):1657. doi: 10.3390/jpm12101657.
6
LiMAx Prior to Radioembolization for Hepatocellular Carcinoma as an Additional Tool for Patient Selection in Patients with Liver Cirrhosis.在肝细胞癌放射性栓塞治疗前使用LiMAx作为肝硬化患者患者选择的附加工具。
Cancers (Basel). 2022 Sep 21;14(19):4584. doi: 10.3390/cancers14194584.
7
Imaging Features of Post Main Hepatectomy Complications: The Radiologist Challenging.肝切除术后并发症的影像学特征:放射科医生面临的挑战
Diagnostics (Basel). 2022 May 26;12(6):1323. doi: 10.3390/diagnostics12061323.
8
Prognostic Significance of Preoperative Integrated Liver Inflammatory Score in Patients with Hepatocellular Carcinoma.术前整合性肝脏炎症评分对肝细胞癌患者的预后意义。
Med Sci Monit. 2022 Jun 21;28:e937005. doi: 10.12659/MSM.937005.

本文引用的文献

1
Dynamic liver function is an independent predictor of recurrence-free survival after curative liver resection for HCC - A retrospective cohort study.动态肝功能是 HCC 根治性肝切除术后无复发生存的独立预测因素——一项回顾性队列研究。
Int J Surg. 2019 Nov;71:56-65. doi: 10.1016/j.ijsu.2019.08.033. Epub 2019 Sep 5.
2
The predictive value of future liver remnant function after liver resection for HCC in noncirrhotic and cirrhotic patients.肝切除术后非肝硬化和肝硬化患者剩余肝功能的预测价值。
HPB (Oxford). 2019 Jul;21(7):912-922. doi: 10.1016/j.hpb.2018.11.012. Epub 2019 Feb 4.
3
Randomized clinical trial comparing liver resection with and without perioperative assessment of liver function.比较有和没有围手术期肝功能评估的肝切除术的随机临床试验。
BJS Open. 2018 Jun 14;2(5):301-309. doi: 10.1002/bjs5.81. eCollection 2018 Sep.
4
Multidetector Computed Tomography for Retrospective, Noninvasive Staging of Liver Fibrosis.多排螺旋 CT 对肝纤维化的回顾性无创分期。
Gastroenterol Clin North Am. 2018 Sep;47(3):569-584. doi: 10.1016/j.gtc.2018.04.012. Epub 2018 Jul 7.
5
Resection or Transplant in Early Hepatocellular Carcinoma.早期肝细胞癌的切除术或移植术。
Dtsch Arztebl Int. 2017 Aug 7;114(31-32):519-526. doi: 10.3238/arztebl.2017.0519.
6
Liver transplantation versus liver resection for hepatocellular carcinoma in intention to treat: An attempt to perform an ideal meta-analysis.肝细胞癌意向性治疗中肝移植与肝切除术的比较:进行理想荟萃分析的尝试。
Liver Transpl. 2017 Jun;23(6):836-844. doi: 10.1002/lt.24758.
7
Effect of Background Liver Cirrhosis on Outcomes of Hepatectomy for Hepatocellular Carcinoma.背景性肝硬化对肝细胞癌肝切除术结局的影响。
JAMA Surg. 2017 Mar 15;152(3):e165059. doi: 10.1001/jamasurg.2016.5059.
8
Randomized clinical trial of chemoembolization plus radiofrequency ablation versus partial hepatectomy for hepatocellular carcinoma within the Milan criteria.随机临床试验:化疗栓塞联合射频消融与肝部分切除术治疗米兰标准范围内的肝细胞癌。
Br J Surg. 2016 Mar;103(4):348-56. doi: 10.1002/bjs.10061. Epub 2016 Jan 18.
9
Non-invasive diagnosis of liver fibrosis and cirrhosis.肝纤维化和肝硬化的非侵入性诊断
World J Gastroenterol. 2015 Nov 7;21(41):11567-83. doi: 10.3748/wjg.v21.i41.11567.
10
Surgical Resection is Better than Transarterial Chemoembolization for Patients with Hepatocellular Carcinoma Beyond the Milan Criteria: A Prognostic Nomogram Study.对于超出米兰标准的肝细胞癌患者,手术切除优于经动脉化疗栓塞术:一项预后列线图研究
Ann Surg Oncol. 2016 Mar;23(3):994-1002. doi: 10.1245/s10434-015-4929-x. Epub 2015 Oct 20.

术前肝功能指导正常肝脏和肝硬化肝脏中的肝癌切除术

Preoperative Liver Function Guiding HCC Resection in Normal and Cirrhotic Liver.

作者信息

Anger Friedrich, Klein Ingo, Löb Stefan, Wiegering Armin, Singh Gurinder, Sperl Dominique, Götze Oliver, Geier Andreas, Lock Johan Friso

机构信息

Department of General, Visceral and Transplantation Surgery, University Hospital of Würzburg, Würzburg, Germany.

Department of Hepatology, University Hospital of Würzburg, Würzburg, Germany.

出版信息

Visc Med. 2021 Mar;37(2):94-101. doi: 10.1159/000508172. Epub 2020 Jun 12.

DOI:10.1159/000508172
PMID:33977098
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8077495/
Abstract

BACKGROUND

Liver resection is the most effective available therapy for patients with hepatocellular carcinoma (HCC). The accurate selection of patients for surgery requires determination of technical resectability and the risk of recurrence, as well as assessment of liver function and functional reserve to avoid postoperative liver failure. Previous studies have underlined the effectiveness and reliability of the LiMAx® test to evaluate liver function preoperatively. Nevertheless, data concerning HCC evaluation are lacking.

METHODS

From 2014 to 2019, 92 patients with HCC underwent additional assessment of liver function using the LiMAx test prior to decision for or against liver resection. Preoperative LiMAx results were compared between cirrhotic and noncirrhotic liver. The clinical decision for surgery was evaluated applying the various liver function parameters available.

RESULTS

Forty-six patients underwent liver resection. The LiMAx results were higher in resected patients (388 vs. 322 µg/kg/h; = 0.004). LiMAx values were an independent risk factor for the presence of liver cirrhosis in multivariate analysis. In 17 patients, surgical treatment was cancelled due to major impairment of liver function. Only 4 out of 46 resected patients presented with post-hepatectomy liver failure (PHLF) grade ≥B. Histologic assessment revealed liver cirrhosis in 10 resected patients without PHLF.

CONCLUSION

Preoperative determination of liver function by the LiMAx test enables effective and safe patient selection for HCC resection in both cirrhotic and noncirrhotic liver.

摘要

背景

肝切除术是肝细胞癌(HCC)患者最有效的现有治疗方法。准确选择手术患者需要确定技术可切除性和复发风险,以及评估肝功能和功能储备以避免术后肝衰竭。先前的研究强调了LiMAx®测试术前评估肝功能的有效性和可靠性。然而,关于HCC评估的数据尚缺乏。

方法

2014年至2019年,92例HCC患者在决定是否进行肝切除术前使用LiMAx测试进行了肝功能的额外评估。比较了肝硬化和非肝硬化肝脏术前LiMAx的结果。应用现有的各种肝功能参数评估手术的临床决策。

结果

46例患者接受了肝切除术。接受肝切除术患者的LiMAx结果更高(388 vs. 322 μg/kg/h;P = 0.004)。在多变量分析中,LiMAx值是肝硬化存在的独立危险因素。17例患者因肝功能严重受损取消了手术治疗。46例接受肝切除术的患者中只有4例出现了≥B级肝切除术后肝衰竭(PHLF)。组织学评估显示,10例接受肝切除术且未发生PHLF的患者存在肝硬化。

结论

通过LiMAx测试术前确定肝功能能够在肝硬化和非肝硬化肝脏中有效且安全地选择HCC切除患者。